SCHEMBL3602915

SCHEMBL3602915

Cc1ccc(C)c2c1OCC2c1ccc(C(C)C)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 2/20 0.40
MAPT P10636 4/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
TP53 P04637 1/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
HPGD P15428 1/20 0.36
NPC1 O15118 1/20 0.34
GAA P10253 1/20 0.34
ATM Q13315 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
LMNA P02545 1/20 0.33
PTGS1 P23219 2/20 0.33
TRPA1 O75762 1/20 0.33
CACNA1C Q13936 1/20 0.33
SLC5A2 P31639 1/20 0.32
PTGS2 P35354 1/20 0.31
ALDH1A1 P00352 2/20 0.31
CYP19A1 P11511 2/20 0.31
CHRM2 P08172 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3600236 0.84 MAPT (0.38) RECQLMAPTSMN1; SMN2TP53CRHBP
SCHEMBL3596242 0.82 MAPT (0.36) RECQLMAPTSMN1; SMN2TP53CRHBP
SCHEMBL3603533 0.80 TP53 (0.34) MAPTSMN1; SMN2TP53HPGDGAA
SCHEMBL3595271 0.80 HPGD (0.34) MAPTSMN1; SMN2TP53HPGD
SCHEMBL3593777 0.78 MAPT (0.35) RECQLMAPTSMN1; SMN2TP53CRHBP
SCHEMBL3607319 0.78 MAPT (0.35) RECQLMAPTSMN1; SMN2TP53CRHBP
SCHEMBL3601085 0.78 MAPT (0.35) RECQLMAPTSMN1; SMN2TP53CRHBP
SCHEMBL3598864 0.77 TP53 (0.33) MAPTSMN1; SMN2TP53HPGD
SCHEMBL3596091 0.77 TP53 (0.33) MAPTSMN1; SMN2TP53HPGD
SCHEMBL3602026 0.77 TP53 (0.33) MAPTSMN1; SMN2TP53HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1637527-B1 CANNABINOID RECEPTOR MODULATOR TAKEDA PHARMACEUTICAL (JP) 2013-04-17 EP disclosed
US-20100240743-A1 CANNABINOID RECEPTOR MODULATOR TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-23 US disclosed
US-7507841-B2 Carbamoylamino-substituted 2,3-dihydro-benzofurans, indoles and benzothiophenes, e.g., (+)-N-((3R)-3-(4-isopropylphenyl)-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide; cerebrovascular disorders TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-03-24 US disclosed
US-20090023800-A1 Cannabinoid receptor modulator TAKEDA PHARMACEUTICAL COMPANY LIMITED 2009-01-22 US disclosed
US-7465815-B2 Cannabinoid receptor modulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-16 US disclosed
US-20080021087-A1 Cannabinoid receptor modulator TAKEDA PHARMACEUTICAL COMPANY LIMITED 2008-01-24 US disclosed
US-20070099990-A1 Cannabinoid receptor modulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-03 US disclosed
EP-1637527-A1 CANNABINOID RECEPTOR MODULATOR Takeda Pharmaceutical Company Limited (JP) 2006-03-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240743-A1 CANNABINOID RECEPTOR MODULATOR CNR1, CNR2, GPR18 RECQL 3437/4885MAPT 4392/4885SMN1; SMN2 4180/4885
US-20080021087-A1 Cannabinoid receptor modulator CNR1, CNR2, GPR18 RECQL 3437/4885MAPT 4392/4885SMN1; SMN2 4180/4885
US-20090023800-A1 Cannabinoid receptor modulator CNR1, CNR2, GPR18 RECQL 3437/4885MAPT 4392/4885SMN1; SMN2 4180/4885
US-20070099990-A1 Cannabinoid receptor modulator CNR1, CNR2, GPR18 RECQL 3437/4885MAPT 4392/4885SMN1; SMN2 4180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.